EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57

Abstract

CLINICAL PROFILE OF CHEMOTHERAPY AMONG CANCER PATIENTS IN A TERTIARY CARE HOSPITAL- AN OBSERVATIONAL STUDY

Dr. Syeda Zaineb Kubra Hussaini*, Dr. Ram Prahlad K M, Riya Regi, Soha Sanobar, R. Sravani and
Ajay Babu

ABSTRACT

Background: Chemotherapy could certainly cure cancer, justifying including it into multimodality regimens with surgery and radiation treatment in the early stages of illness to give a therapeutic benefit. Since its inception, the primary barriers to chemotherapy's therapeutic success have been toxicity to normal tissues, tumour heterogeneity, and the development of cellular drug resistance.[1] Objective: To study the prognosis of chemotherapy, observe the diagnostic criteria of various types of cancer, and analyse various types of chemotherapy used in all types of cancer. Methods: A Hospital-based observational study of chemotherapy was conducted in tertiary care hospital for 6 months duration, with a sample size of 50 patients in the oncology inpatient and day care department of a tertiary care hospital. To begin, only medications that are somewhat successful against the same tumour when taken alone should be chosen for usage in combination. If they are available, medicines that cause some degree of full remission are recommended over those that cause just partial responses. When numerous medications of the same class are available and similarly effective, medication should be chosen based on its toxicity, which should not overlap with the toxicity of other medications to be used in combination. Results and Discussion: In this Prospective observational study, females (58%) were found to be more likely to suffer from cancer than male patients. Our study also revealed that 36-45 age group patients (30%)were found to be likely affected more in a population (n=50). Based on body weight difference between pre and post-chemotherapy,40-60 age group patients were found to have more weight difference (30%). the number of patients diagnosed with carcinoma was high (76%). Pre-medications of chemotherapy found that Dexamethasone (68%) and Ondansetron (68%) were mostly prescribed along with Ranitidine (30%). Conclusion: The study shows that a combination of Adriamycin and cyclophosphamide were the most commonly prescribed chemotherapeutic agents used for breast carcinoma for 22% of breast cancer patients and also the combination of cisplatin and paclitaxel which is a mitotic inhibitor were most commonly prescribed chemotherapeutic agents used for 16% of lung cancer.

Keywords: Chemotherapy, Carcinoma, Sarcoma.


[Full Text Article]

INDEXING

NEWS & UPDATION

  • EJPMR: JANUARY ISSUE PUBLISHED

    JANUARY issue has been successfully launched on 1 JANUARY 2023.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 January 2023 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database